IP Library › Granted Patent US 12,521,056
Granted Patent B2
US 12,521,056 · App. 17/885,812 · Granted Jan 13, 2026

System, device and method for determining and/or assessing brain related conditions based on pupil light response

Inventors: Ygal Rotenstreich (Kfar Bilu, IL); Ifat Sher (Shoham, IL)
Assignee: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
A61B5/4064A61B3/0008A61B3/112A61B5/7267
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,521,056
App. No.
17/885,812
Granted
Jan 13, 2026
Kind
B2
Abstract

Provided herein are systems, devices and methods for monitoring the progression of, determining and/or assessing brain related conditions in a subject based on pupil light responses (PLRs) to focal central and peripheral chromatic light stimuli, in particular, by classifying the PLR based on one or more PLR parameter values, wherein the classifying allows monitoring the progression of, determining and/or assessing the brain related condition.

Claims (48)

1 . A non-invasive method for monitoring the progression of, determining and/or assessing a brain related condition of a subject, based on pupil light response (PLR) to chromatic light stimuli, under mesopic light conditions, the method comprising:

determining, for each stimuli, a baseline pupil size of an eye of the subject;

applying high intensity blue light, low intensity blue light and red light stimuli to one or more regions of the visual field of the eye, the light stimuli configured to induce a response in the pupil;

obtaining a value for parameters related to induced changes in the pupil size in response to the light stimuli, said parameters comprise Maximal Contraction Velocity (MCV) of the pupil, Latency of MCV (LMCV) of the pupil and Percentage of Pupil Relaxation (PPR);

normalizing, based on the determined baseline pupil size, the value of the parameters; and

classifying the PLR based on the parameters values;

wherein said classifying results in monitoring the progression of, determining and/or assessing the brain related condition.

2 . The method of claim 1 , wherein the brain related condition comprises: brain tumor, optic neuritis, neurodegenerative conditions, traumatic brain injury, stroke, intracranial lesions, intracranial pressure or pseudotumor cerebri.

3 . The method of claim 2 , wherein the neurodegenerative conditions are selected from the group consisting of: Alzheimer's disease (AD), Multiple Sclerosis (MS), Parkinson disease (PD), and fragile-X related cognitive decline.

4 . The method of claim 1 , wherein the parameters further comprise one or more of: Percent of Pupil Contraction (PPC), Pupil Response Latency (PRL), Maximal Relaxation Velocity (MRV), Latency of MRV (LMRV), Maximal Contraction Acceleration (MCA), Latency of MCA (LMCA), Maximal Relaxation Acceleration (MRA), Latency of MRA (LMRA), Maximal Relaxation Deceleration (MRD), Latency of Maximal Relaxation Deceleration (LMRD), Area of Curve (AC), Latency of Maximal Pupil Contraction (LMP), Maximal Contraction Deceleration (MCD), Latency of MCD (LMCD), Max Pupil Size (Max_PS), or Min Pupil Size (Min_PS).

5 . The method of claim 1 , further comprising applying curve fitting to data associated with pupil size in response to light stimulation.

6 . The method of claim 1 , wherein the classification comprises applying at least one algorithm to one or more selected parameter values and obtaining a brain related condition.

7 . The method of claim 1 , wherein each light stimuli comprises between 1 and 228 individual light stimuli, each applied to a different location of the visual field.

8 . The method of claim 1 , wherein the light stimuli are presented for a period of time of between about 0.1 to 10 seconds.

9 . The method of claim 1 , wherein the regions of the visual field comprise a central visual field ranging between about 0-10 degrees; and/or wherein the regions of the visual field comprise a peripheral visual field greater than about 10 degrees.

10 . The method of claim 1 , further comprising providing an initial pre-determined light stimuli at an initial illumination, duration and visual field locations, configured to determine a possibility of the subject having a brain related condition, prior to applying the blue and red light stimuli, wherein applying the blue and red light stimuli to one or more regions of visual field of the eye is based, at least in part, on the determined possibility of the subject having a brain related condition.

11 . The method of claim 1 , wherein applying the blue and/or red light stimuli to one or more regions of the visual field of the eye comprises selecting a subset of light stimuli based on a location of the light stimuli in relation to the visual field; and/or one or more of: selecting the wavelength of each individual light of the light stimuli, selecting the intensity of each individual light of the light stimuli, selecting the ratio of blue to red light stimuli, or selecting the duration of illumination of each individual light of the light stimuli.

12 . The method of claim 1 , wherein applying the blue and/or red light stimuli to one or more regions of visual field of the eye comprises applying blue and/or red light stimuli in at least two intervals, said at least two intervals are about 2 to 120 seconds apart.

13 . The method of claim 12 , wherein each interval comprises a different subset of light stimuli, different wavelengths of light stimuli, and/or different intensities of light stimuli.

14 . The method of claim 1 , wherein the method comprises determining a risk for developing Alzheimer's disease, and the risk is determined based on at least one of: the MCV parameter in the central region of the visual field in response to a high intensity blue light stimuli, the PRL parameter in response to low intensity blue light in the periphery, the PRL parameter in response to blue light, the PRL parameter in response to red light, the LMCA parameter in response to blue light, the LMCA parameter in response to red light, the LMCD parameter in response to blue light, the LMCD parameter in response to red light, the LMP parameter in response to blue light, the LMP parameter in response to red light, or the MCV parameter in response to blue light.

15 . The method of claim 1 , further comprising inputting one or more selected values of at least one of the parameters to a machine learning algorithm(s) configured to classify the subject as having a brain related condition or not having a brain related condition.

16 . The method of claim 15 , further comprising classifying, using the machine learning algorithm, the brain related condition into types and/or levels of severity and/or progression of the condition based, at least in part, on the parameters and selected values thereof.

17 . A pupillometer device for monitoring the progression of, determining and/or assessing a brain related condition of a subject, based on pupil light response to chromatic light stimuli, under mesopic light conditions, the pupilometer device comprising:

a plurality of chromatic beam emitters configured to generate red and/or blue light stimuli at predetermined locations of the visual field;

at least one camera configured to detect pupil response; and

a control unit in communication with the plurality of chromatic beam emitters and the at least one camera, wherein the control unit is configured to

apply high intensity blue light, low intensity blue light and red light stimuli to one or more regions of the visual field of the eye;

for each stimuli, determine a baseline pupil size of an eye of the subject;

determine a value for parameters related to induced changes in the pupil size in response to the light stimuli, said parameters comprise Maximal Contraction Velocity (MCV) of the pupil, Latency of MCV (LMCV) of the pupil and Percentage of Pupil Relaxation (PPR);

normalize, based on the determined baseline pupil size, the value of the parameters; and

classify the PLR based on the parameter values, wherein said classifying allows monitoring the progression of, determining and/or assessing the brain related condition.

18 . The device of claim 17 , wherein the brain related condition comprises: brain tumor, optic neuritis, neurodegenerative conditions, traumatic brain injury, stroke, intracranial lesions, intracranial pressure or pseudotumor cerebri.

19 . The device of claim 17 , wherein the parameters further comprise: Percent of Pupil Contraction (PPC), Pupil Response Latency (PRL), Maximal Relaxation Velocity (MRV), Latency of MRV (LMRV), Maximal Contraction Acceleration (MCA), Latency of MCA (LMCA), Maximal Relaxation Acceleration (MRA), Latency of MRA (LMRA), Maximal Relaxation Deceleration (MRD), Latency of Maximal Relaxation Deceleration (LMRD), Area of Curve (AC), Latency of Maximal Pupil Contraction (LMP), Maximal Contraction Deceleration (MCD), Latency of MCD (LMCD), Max Pupil Size (Max_PS), Min Pupil Size (Min_PS), or any combination thereof.

20 . The device of claim 17 , wherein each light stimuli comprises between 1 and 228 individual light stimuli, each applied to a different location of the visual field.

21 . The device of claim 17 , wherein the regions of the visual field comprise a central visual field ranging between about 0-10 degrees and/or a peripheral visual field is greater than about 10 degrees.

22 . The device of claim 17 , wherein the control unit is further configured to select a subset of light stimuli based on at least the location of the light stimuli in relation to the visual field.

23 . The device of claim 17 , wherein the control unit is further configured to select the wavelength of each individual light of the light stimuli, the intensity of each individual light of the light stimuli, the ratio of blue to red light stimuli, and/or the duration of illumination of each individual light of the light stimuli.

24 . The device of claim 17 , wherein the control unit is in communication with a server or memory module comprising instructions for identifying, assessing and/or monitoring the progression of a brain related condition.

25 . The device of claim 17 , wherein the control unit is configured to classify, based on a machine learning algorithm, one or more selected values of at least one of the parameters as being associated with a brain related condition and/or a progression of a brain related condition.

26 . A system for monitoring the progression of, determining and/or assessing a brain related condition of a subject, based on pupil light response to chromatic light stimuli under mesopic light conditions, the system comprising:

at least one hardware processor; and

a non-transitory computer-readable storage medium having stored thereon program code, the program code executable by the at least one hardware processor to:

receive data associated with red and/or blue light stimuli generated at predetermined locations of the visual field of the subject, wherein the red and/or blue light stimuli comprises high intensity blue light, low intensity blue light and red light stimuli applied to one or more regions of the visual field of the eye;

receive data associated with the pupil size of the subject, for each stimuli;

determine a value for parameters related to induced changes in the pupil size in response to the light stimuli, the parameters comprise Maximal Contraction Velocity (MCV) of the pupil, Latency of MCV (LMCV) of the pupil and Percentage of Pupil Relaxation (PPR);

normalize, based on the base line pupil size, a value of the parameters; and

input one or more of selected values of at least one of the parameters to an algorithm configured to classify the subject as having a brain related condition or not having a brain related condition based, at least in part, on at least one value of parameters.

27 . The system according to claim 26 , wherein the algorithm is a machine learning algorithm configured to classify the brain related condition into types and/or levels of severity and/or progression of the condition based, at least in part, on the value of the parameters.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Aug 28, 2022
From: ROTENSTREICH, YGAL; SHER, IFAT
To: TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD.
Reel/Frame 060920/0321 →
Continuity (4)
Continuation In Part PCTIL2021050170 · Feb 11, 2021
Provisional Application 63232279 · Aug 12, 2021
Provisional Application 62972668 · Feb 11, 2020
Related Publication 20230050186A1 · Feb 16, 2023
References Cited (86)
US 6669651B1 · Fukushima et al. · 2003 [cited by applicant]
US 20150245766A1 · Rennaker et al. · 2015 [cited by applicant]
US 20160262611A1 · Rotenstreich · 2016 [cited by applicant]
US 20170347878A1 · Milea et al. · 2017 [cited by applicant]
US 20180249904A1 · Rotenstreich et al. · 2018 [cited by applicant]
US 20190191995A1 · Giovinazzo · 2019 [cited by examiner]
US 20200337556A1 · Uys · 2020 [cited by examiner]
US 20210393122A1 · Milea · 2021 [cited by examiner]
EP 1127534A2 · 2001 [cited by applicant]
WO 2017123710A1 · 2017 [cited by applicant]
WO 2018203828A1 · 2018 [cited by applicant]
Berman, G. et al., “Decreased retinal sensitivity in depressive disorder: a controlled study”, Acta Psychiatrica Scandinavica, vol. 137(3):231-240. Jan. 15, 2018. Munksgaard, Copenhagen, Denmark. doi: 10.1111/acps.12851. [cited by applicant]
Palanca-Castan, N. et al., “Chromatic pupillometry for the characterization of the pupillary light reflex in Octodon degus”, Experimental Eye Research, Academic Press Ltd., London, vol. 190:107866., Nov. 2, 2019. doi: 1… [cited by applicant]
Wimo et al (2013) The worldwide economic impact of dementia, Alzheimers Dement 9:1-11.e3; http://dx.doi.org/10.1016/j.jalz.2012.11.006. [cited by applicant]
Hsu et al (2017) Primary and Secondary Prevention Trials in Alzheimer Disease: Looking Back, Moving Forward, Curr Alzheimer Res., 14(4):426-440; doi:10.2174/1567205013666160930112125. [cited by applicant]
Cummings et al (2007) Disease-modifying therapies for Alzheimer disease: challenges to early intervention, Neurology, 69:1622-1634; DOI: 10.1212/01.wnl.0000295996.54210.69. [cited by applicant]
Payami et al (1997) A prospective study of cognitive health in the elderly (Oregon Brain Aging Study): effects of family history and apolipoprotein E genotype, Am J Hum Genet, 60:948-956; PMID: 9106542. [cited by applicant]
VanDuijn et al (1991) Familial aggregation of Alxheimer's disease and related disorder: a collaborative re-analysis of case-control studies, Int J Epidemiol, 20 Suppl2:S13-20; https://doi.org/10.1093/ije/20.Supplement_2… [cited by applicant]
Green et al (2002) Risk of dementia among white and African American relatives of patients with Alzheimer disease, JAMA, 287:329-336; DOI: 10.1001/jama.287.3.329. [cited by applicant]
Bendlin et al (2010) Midlife predictors of Alzheimer's disease, Maturitas, 65:131-137; doi:10.1016/j.maturitas.2009.12.014. [cited by applicant]
Scarabino et al (2016) Influence of family history of dementia in the development and progression of late-onset Alzheimer's disease, Am J Med Genet B, Neuropsychiatr Genet, 171(2):250-256; DOI 10.1002/ajmg.b.32399. [cited by applicant]
Bondareff et al (1987) Neuronal degeneration in locus ceruleus and cortical correlates of Alzheimer disease, Alzheimer Dis Assoc Disord, 1:256-262; DOI: 10.1097/00002093-198701040-00005. [cited by applicant]
Den Haan et al (2018) Amyloid-beta and phosphorylated tau in post-mortem Alzheimer's disease retinas, Acta Neuropathol Commun, 6:147; https://doi.org/10.1186/s40478-018-0650-x. [cited by applicant]
La Morgia et al (2016) Melanopsin retinal ganglion cell loss in Alzheimer disease, Ann Neurol, 79:90-109; DOI: 10.1002/ana.24548. [cited by applicant]
Scinto et al (1999) Focal pathology in the Edinger-Westphal nucleus explains pupillary hypersensitivity in Alzheimer's disease, Acta Neuropathol, 97:557-564; DOI: 10.1007/s004010051031. [cited by applicant]
Munch et al (2013) Intrinsically photosensitive retinal ganglion cells: classification, function and clinical implications, Curr Opin Neurol, 26:45-51; DOI:10.1097/WCO.0b013e32835c5e78. [cited by applicant]
Schmidt et al (2011) Melanopsin-positive intrinsically photosensitive retinal ganglion cells: from form to function, J Neurosci, 31:16094-16101; DOI:10.1523/JNEUROSCI.4132-11.2011. [cited by applicant]
Guler et al (2008) Melanopsin cells are the principal conduits for rod-cone input to non-image-forming vision, Nature, 452:102-105; doi:10.1038/nature06829. [cited by applicant]
Chougule et al (2019) Light-Inducted Pupillary Responses in Alzheimer's Disease, Front Neurol, 10:360; doi:10.3389/fneur.2019.00360. [cited by applicant]
Prettyman et al (1997) Altered pupillary size and darkness and light reflexes in Alzheimer's disease, J Neurol Neurosurg Psychiatry, 62:665-668; DOI: 10.1136/jnnp.62.6.665 Free PMC article. [cited by applicant]
Frost et al (2013) Pupil Response Biomarkers for Early Detection and Monitoring of Alzheimers Disease, Current Alzheimer Research, 10:931-939; DOI: 10.2174/15672050113106660163. [cited by applicant]
Ferrario et al (1998) Is videopupillography useful in the diagnosis of Alzheimer's disease?, Neurology, 50:642-644; DOI: 10.1212/wnl.50.3.642. [cited by applicant]
Bittner et al (2014) Repetitive pupil light reflex: potential marker in Alzheimer's disease?, J Alzheimers Dis, 12:1469-1477; DOI: 10.3233/JAD-140969. [cited by applicant]
Granholm et al (2003) Tropicamide effects on pupil size and pupillary light reflexes in Alzheimer's and Parkinson's disease, Int J Psychophysiol, 47:95-115; DOI: 10.1016/s0167-8760(02)00122-8. [cited by applicant]
Fotiou et al (2007) Pupil reaction to light in Alzheimer's disease: evaluation of pupil size changes and mobility, Aging Clin Exp Res, 19: 364-371; DOI: 10.1007/BF03324716. [cited by applicant]
Fotiou et al (2009) Cholinergic deficiency in Alzheimer's and Parkinson's disease: evaluation with pupillometry, Int J Psychophysiol, 73: 143-149; doi:10.1016/j.ijpsycho.2009.01.011. [cited by applicant]
The Europe PMC Consorium (2014) Europe Pmc: A full text literature database for the life sciences and platform for innovation, Nucleic Acids Research, vol. 43 Database Issue, D1042-D1048; doi: 10.1093/nar/gku1061. [cited by applicant]
Frost et al (2013) Pupil response biomarkers distinguish amyloid precursor protein mutation carriers from non-carriers, Curr Alzheimer Res 10:790-796; doi: 10.2174/15672050113109990154. [cited by applicant]
Frost et al (2017) Evaluation of cholinergic deficiency in preclinical alzheimer's disease using pupillometry, J Ophthalmol, 7935406; https://doi.org/10.1155/2017/7935406. [cited by applicant]
Fotiou et al (2015) Evaluation of the cholinergic hypothesis in Alzheimer's disease with neuropsychological methods, Aging Clin Ex Res, 27:727-733; doi: 10.1007/s40520-015-0321-8. [cited by applicant]
Van Stavern et al (2019) Pupillary light reaction in preclinical Alzheimer's disease subjects compared with normal ageing controls, Br J Ophthalmol, 103:971-975; doi:10.1136/bjophthalmol-2018-312425. [cited by applicant]
Kardon et al (2009) Chromatic pupil responses: preferential activation of the melanopsin-mediated versus outer photoreceptor-mediated pupil light reflex, Ophthalmology, 116:1564-1573; doi:10.1016/j.ophtha.2009.02.007. [cited by applicant]
Park et al (2011) Toward a clinical protocol for assessing rod, cone, and melanopsin contributions to the human pupil response, Visual Neurophysiology, 52:6624-6635; DOI:10.1167/iovs.11-7586. [cited by applicant]
Gooley et al (2012) Melanopsin and rod-cone photoreceptors play different roles in mediating pupillary light responses during exposure to continuous light in humans, J Neurosci, 32:14242-14253; DOI:10.1523/JNEUROSCI.132… [cited by applicant]
Rukmini et al (2019) Chromatic pupillometry methods for assessing photoreceptor health in retinal and optic nerve diseases, Front Neurol, 10:76; doi: 10.3389/fneur.2019.00076. [cited by applicant]
Romagnoli et al (2020) Chromatic pupillometry findings in alzheimer's disease, Front Neurosci, 14:780; doi:10.3389/fnins.2020.00780. [cited by applicant]
Kawasaki et al (2020) Early-Stage Alzheimer's Disease Does Not Alter Pupil Responses to Colored Light Stimuli, J Alzheimers Dis, 75:1273-1282; DOI 10.3233/JAD-200120. [cited by applicant]
Oh et al (2019) Pupillometry evaluation of melanopsin retinal ganglion cell function and sleep-awake activity in pre-symptomatic Alzheimer's disease, PLoS One, 14:e0226197; https://doi.org/10.1371/journal.pone.0226197. [cited by applicant]
Chibel et al (2016) Chromatic Multifocal Pupillometry for Objective Perimetry and Diagnosis of Patients with Retinitis Pigmentosa, Ophthalmology, 123:1898-1911; http://dx.doi.org/10.1016/j.ophtha.2016.05.038. [cited by applicant]
Ben Ner et al (2019) Chromatic pupilloperimetry for objective diagnosis of Best vitelliform macular dystrophy, Clin Ophthalmol, 13:465-475; DOI: 10.2147/OPTH.S191486. [cited by applicant]
Sher et al (2020) Chromatic pupillometry measures correlate with visual acuity and visual field defects in retinitis pigmentosa patients, Trans Vis Sci Tech, 9:10; https://doi.org/10.1167/tvst.9.8.10. [cited by applicant]
Yahia et al (2018) Effect of Stimulus Intensity and Visual Field Location on Rod- and-Cone-Mediated Pupil Response to Focal Light Stimuli, Invest Ophthalmol Vis Sci, 59:6027-6035; https://doi.org/10.1167/iovs.18-23767. [cited by applicant]
Skaat et al (2013) Pupillometer-based objective chromatic perimetry in normal eyes and patients with retinal photoreceptor dystrophies, Invest Ophthalmol Vis Sci, 54: 2761-2770; DOI:10.1167/iovs.12-11127. [cited by applicant]
Freund et al (1997) A Decision-Theoretic Generalization of On-Line Learning and an Application to Boosting, Journal of Comuter and System Sciences, 55:119-139; https://doi.org/10.1006/jcss.1997.1504. [cited by applicant]
Kalton, G (1986) The treatment of missing survey data, Surv Methodol; available online at: https://www150.statcan.gc.ca/n1/en/pub/12-001-x/1986001/article/14404-eng.pdf?st=n_FL89o. [cited by applicant]
Kalton et al (1982) Imputing for missing survey responses, Proceedings of the section on survey research, pp. 22-31; available online at: https://www.istat.it/en/files/2014/05/1982-004-ASA.pdf. [cited by applicant]
Diciccio et al (1996) Bootstrap confidence intervals, Statistical Science vol. 11, No. 3 pp. 189-228; http://www.jstor.org/stable/2246110. [cited by applicant]
Ferreira-Vieira et al (2016) Alzheimer's disease: Targeting the Cholinergic System, Curr Neuropharmacol, 14:101-115; doi: 10.2174/1570159X13666150716165726. [cited by applicant]
Scinto et al (2001) Selective cell loss in Edinger-Westphal in asymtomatic elders and Alzheimer's patients, Neurobiol Aging, 22:729-736; DOI: 10.1016/s0197-4580(01)00235-4. [cited by applicant]
McAnany et al (2021) Rod pathway and cone pathway retinal dysfunction in the 5xFAD mouse model of Alzheimer's disease, Sci Rep, 11:4824; https://doi.org/10.1038/s41598-021-84318-2. [cited by applicant]
Do et al (2019) Elovanoids counteract oligomeric β-amyloid-induced gene expression and protect photoreceptors, Proc Natl Acad Sci USA, 116:24317-24325; www.pnas.org/cgi/doi/10.1073/pnas.1912959116. [cited by applicant]
Fan et al (2009) Weak gender effects on transient pupillary light reflex, Auton Neurosci, 147:9-13; doi:10.1016/j.autneu.2008.12.010. [cited by applicant]
Hattar et al (2002) Melanopsin-containing retinal ganglion cells: architecture, projectins, and instrinsic photosensitivity, Science, 295(5557):1065-1070; doi:10.1126/science.1069609. [cited by applicant]
Lucas et al (2003) Diminished pupillary light reflex at high irradiances in melanopsin-knockout mice, Sciences, 299 (5604):245-247; DOI: 10.1126/science.1077293. [cited by applicant]
McDougal, DH (2008) The role of melanopsin containing retinal ganglion cells in the pupillary responses of human and non-human primates, The University of Alabama at Birmingham. [cited by applicant]
Dacey et al (2005) Melanopsin-expressing ganglion cells in primate retina signal colour and irradiance and project to the LGN, Nature, 433(7027):749-754; https://doi.org/10.1038/nature03387. [cited by applicant]
Remington, LA (1998) Clinical anatomy of the visual system, Newton, MA: Butterworth-Heinemann. [cited by applicant]
Belliveau et al (2020) Pupillary Light Reflex, in StatPearls, Treasure Island (FL): StatPearls Publishing. [cited by applicant]
Thompson et al (1991) Asymmetry of pupillomotor input, Eye 5 (Pt 1):36-39; https://doi.org/10.1038/eye.1991.7. [cited by applicant]
Wilhelm et at (2002) Pupil response components: studies in patients with Parinaud's syndrome, Brain, vol. 125, Issue 10, Oct. 2002, pp. 2296-2307, https://doi.org/10.1093/brain/awf232. [cited by applicant]
Skorkovska et al (2009) How sensitive is pupil campimetry in hemifield loss? Graefes Arch. Clin. Exp. Ophthalmol., 247(7):947-953; DOI 10.1007/s00417-009-1040-7. [cited by applicant]
Kawasaki et al (2010) Pupillographic investigation of the reletive afferent pupillary defect associated with a midbrain lesion, Ophthalmology, 117(1):175-179; doi:10.1016/j.ophtha.2009.06.053. [cited by applicant]
Chen et al (2011) Pupillary reactivity as an early indicator of increased intracranial pressure: The introduction of the Neurological Pupil index, Surg Neurol Int, 2:82; DOI: 10.4103/2152-7806.82248. [cited by applicant]
Kim et al (2018) Implication of neurological pupil index for monitoring of brain edema, Acute Crit. Care, 33(1):57-60; https://doi.org/10.4266/acc.2017.00213. [cited by applicant]
Park et al (2016) The pupillary light reflex in idiopathic intracranial hypertension, Invest. Ophthalmol. Vis. Sci., 57(1):23-29; DOI:10.1167/iovs.15-18181. [cited by applicant]
Papangelou et al (2018) Automated pupillometry and detection of clinical transtentorial brain herniation: A case series, Mil. Med., 183(1-2):e113-e121; DOI:10.1093/milmed/usx018. [cited by applicant]
Chen et al (2014) Infrared pupillometry, the Neurological Pupil index and unilateral pupillary dilation after traumatic brain injury: implications for treatment paradigms, Springerplus, 3:548; http://www.springerplus.co… [cited by applicant]
Master et al (2020) Utility of Pupillary Light Reflex Metrics as a Physiologic Biomarker for Adolescent Sport-Related Concussion, JAMA Ophthalmol. [published online ahead of print: Sep. 24, 2020] doi:10.1001/iamaophthal… [cited by applicant]
Paulus et al (2013) Pupillary reflex measurement predict insufficient analgesia before endotracheal sunctioning in critically ill patients, Crit. Care, 17(4):R161; http://ccforum.com/content/17/4/R161. [cited by applicant]
Aissou et al (2012)Objective assessment of the immediate postoperative analgesia using pupillary reflex measurement: a prospective and observational study, Anesthesiology, 116(5):1006-1012; DOI: 10.1097/ALN.0b013e318251… [cited by applicant]
Park et al (2015) Effect of stimulus size and luminance on the rod-, cone-, and melanopsin-mediated pupillary light reflex, J. Vis. 15(3). Doi:10.1167/15.3.13. [cited by applicant]
Sharpe, JA (1985) Visual dysfunction with basal skull tumours, Can J Neurol Sci, 12(4):332-335; DOI: 10.1017/s0317167100035472. [cited by applicant]
Repka et al (1989) Visual outcome after surgical removal of craniopharyngiomas, Ophthalmology, 96(2):195-199; doi: 10.1016/s0161-6420(89)32914-9. [cited by applicant]
Lustig et al (2022) Machine learning for comprehensive prediction of high risk for Alzheimer's diseased based on chromatic pupilloperimetry, Scientific Reports, 12; https://doi.org/10.1038/s41598-022-13999-0. [cited by applicant]
PCT International Search Report for International Application No. PCT/IL2021/050170, mailed Apr. 26, 2021, 3pp. [cited by applicant]
PCT Written Opinion for International Application No. PCT/IL2021/050170, mailed Apr. 26, 2021, 8pp. [cited by applicant]